



PRESS RELEASE

Ascendis Pharma A/S Announces Upcoming Investor Presentations in September

COPENHAGEN, Denmark, September 1, 2022 (GLOBE NEWSWIRE) – Ascendis Pharma A/S (Nasdaq: ASND) announced today that the company is scheduled to participate in three upcoming investor conferences in September.

Details:

Event	Citi's 17th Annual BioPharma Conference
Location	Boston, MA
Date	Wednesday, September 7, 2022
Time	3:30-4:15 p.m. Eastern Time / 12:30-1:15 p.m. Pacific Time
Speaker(s)	Scott Smith, Senior Vice President, Chief Financial Officer
Event	2022 Wells Fargo Healthcare Conference
Location	Boston, MA
Date	Thursday, September 8, 2022
Time	8:35-9:05 a.m. Eastern Time / 5:35-6:05 a.m. Pacific Time
Speaker(s)	Scott Smith, Senior Vice President, Chief Financial Officer
Event	Morgan Stanley 20th Annual Global Healthcare Conference
Location	New York, NY
Date	Tuesday, September 13, 2022
Time	1:30-2:00 p.m. Eastern Time / 10:30-11:00 a.m. Pacific Time
Speaker(s)	Jan Mikkelsen, President and Chief Executive Officer and Scott Smith, Senior Vice President, Chief Financial Officer

A live webcast of the events will be available on the Investors & News section of the Ascendis Pharma website at <https://investors.ascendispharma.com>. A webcast replay will also be available on this website shortly after conclusion of each event for 30 days.

About Ascendis Pharma A/S

Ascendis Pharma is applying its innovative platform technology to build a leading, fully integrated, global biopharmaceutical company focused on making a meaningful difference in patients' lives. Guided by its core values of patients, science and passion, the company uses its TransCon technologies to create new and potentially best-in-class therapies. Ascendis is headquartered in Copenhagen, Denmark, and has additional facilities in Heidelberg and Berlin, Germany; Palo Alto and Redwood City, California; and Princeton, New Jersey. Please visit www.ascendispharma.com to learn more.

Forward-Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Ascendis' future operations, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to (i) Ascendis' ability to apply its platform technology to build a leading, fully integrated global biopharmaceutical company, and (ii) Ascendis' use of its TransCon technologies to create new and potentially best-in-class therapies. Ascendis may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Ascendis makes, including the following: dependence on third party manufacturers, distributors, and service providers for Ascendis products and product candidates; unforeseen safety or efficacy results in its development programs or on-market products; unforeseen expenses related to commercialization of any approved Ascendis products; unforeseen expenses related to Ascendis' development programs; unforeseen selling, general and administrative expenses, other research and development expenses and Ascendis' business generally; delays in the development of its development programs related to manufacturing, regulatory requirements, speed of patient recruitment or other unforeseen delays; Ascendis' ability to obtain additional funding, if needed, to support its business activities and the effects on its business from the worldwide COVID-19 pandemic and or ongoing conflicts such as that in the region surrounding Ukraine and Russia. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ascendis' business in general, see Ascendis' Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (SEC) on March 2, 2022 and Ascendis' other future reports filed with, or submitted to, the SEC. Forward-looking statements do not reflect the potential impact of any future licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments that Ascendis may enter into or make. Ascendis does not assume any obligation to update any forward-looking statements, except as required by law.

Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo and TransCon are trademarks owned by the Ascendis Pharma Group. © September 2022 Ascendis Pharma A/S.

Investor Contacts:

Tim Lee

Ascendis Pharma

+1 (650) 374-6343

tle@ascendispharma.com

Patti Bank

ICR Westwicke

+1 (415) 513-1284

patti.bank@westwicke.com

ir@ascendispharma.com

Media Contact:

Melinda Baker

Ascendis Pharma

+1 (650) 709-8875

media@ascendispharma.com